share_log

Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry

Advanced Health Intelligence Signs Letter of Intent to Develop and Deploy a Digital Underwriting Solution For the Insurance Industry

Advanced Health Intelligence簽署意向書,爲保險業開發和部署數字承保解決方案
newsfile ·  2023/09/20 18:58

Highlights

亮點

  • AHI signs a letter of Intent with Unisure.
  • AHI 與 Unisure 簽署了一份意向書。
  • SCOR (SCR.FP) and Unisure to collaborate with AHI.
  • SCOR(SCR.FP)和Unisure將與AHI合作。
  • SCOR is one of the world's largest Reinsurers.
  • SCOR是全球最大的再保險公司之一。
  • AHI will deploy a digital underwriting capability using AHI's Biometric Health Assessment.
  • AHI將使用AHI的生物識別健康評估部署數字承保能力。
  • AHI is to Digitise phenotypical Biometric data for insurance underwriting purposes.
  • AHI將用於保險承保目的的表型生物識別數據數字化。

South Perth, Australia--(Newsfile Corp. - September 20, 2023) - Advanced Health Intelligence Ltd (ASX: AHI) (NASDAQ: AHI) ("AHI" or "the Company") is pleased to inform shareholders that the Company has entered a Letter of Intent (LOI) with UK-based Unisure Group to design, develop and deploy the AHI Biometric Health Assessment (BHA).

澳大利亞南珀斯--(Newsfile Corp.,2023 年 9 月 20 日)- 高級健康情報有限公司 (澳大利亞證券交易所: AHI) (納斯達克:AHI)(“AHI” 或 “公司”) 很高興地通知股東,該公司已與總部位於英國的Unisure集團簽訂了意向書(LOI),以設計、開發和部署AHI生物識別健康評估(BHA)。

The LOI is a result of exploratory discussions between AHI, SCOR and Unisure over several months, resulting in SCOR partnering with Unisure to develop and deploy the digital application with AHI.

意向書是AHI、SCOR和Unisure在幾個月內進行探索性討論的結果,最終SCOR與Unisure合作,使用AHI開發和部署數字應用程序。

Unisure and AHI have executed a Letter of Intent to develop and deploy a world-first digital underwriting solution utilising AHI's revolutionary smartphone-based biometric health risk assessment. The intent of the relationship is to create a series of innovative insurance offerings by leveraging AHI's technology with SCOR's wealth of Reinsurance knowledge to service the global retail insurance market. Partnering with Unisure and SCOR presents a unique opportunity that will utilise the proprietary AHI digital blood biomarkers and phenotypical data combined with insurers' rich actuarial and underwriting data to develop and design new digital underwriting solutions.

Unisure和AHI簽署了一份意向書,利用AHI革命性的基於智能手機的生物識別健康風險評估,開發和部署全球首個數字承保解決方案。雙方合作的目的是利用AHI的技術和SCOR豐富的再保險知識,爲全球零售保險市場提供服務,從而創建一系列創新的保險產品。與Unisure和SCOR合作提供了一個難得的機會,它將利用專有的AHI數字血液生物標誌物和表型數據,再加上保險公司豐富的精算和承保數據,開發和設計新的數字承保解決方案。

The collaboration will result in SCOR and Unisure deploying AHI's technology to digitally assess the health risk across a minimum of 5,000 individuals as part of a health screening for insurance requirements.

此次合作將促使SCOR和Unisure部署AHI的技術,以數字方式評估至少5,000人的健康風險,這是保險要求健康篩查的一部分。

The intention is that this will be the first in a series of AHI's insurance market product developments to digitise risk underwriting, which can be used to augment traditional blood pathology underwriting over time. The breadth of AHI's 61 health outputs, resulting in 41 biometric captures across five major health and disease risk categories - cardio-respiratory, body composition, estimated blood biomarkers, metabolic health and mental health offers comprehensive insights for morbidity and mortality risk highly relevant to health and life policy pricing. AHI is in a distinctive position to work alongside insurers to cost-effectively unlock the large, unpenetrated, and un-serviced middle market where traditional medical underwriting is now deemed too slow and expensive.

其意圖是,這將是AHI保險市場一系列產品開發中第一個將風險承保數字化的產品,隨着時間的推移,風險承保可用於增強傳統的血液病理學承保。AHI的61項健康產出涵蓋了五個主要的健康和疾病風險類別——心肺呼吸、身體成分、估計的血液生物標誌物、代謝健康和心理健康,爲與健康和人壽保單定價高度相關的發病率和死亡風險提供了全面的見解。AHI處於獨特的地位,可以與保險公司合作,以具有成本效益的方式開拓龐大、未滲透且沒有服務的中間市場,在這個市場中,傳統的醫療承保現在被認爲過於緩慢和昂貴。

Dylan Garnett, Chief Innovation Officer at AHI, said:

AHI首席創新官迪倫·加內特表示:

"With more than two decades of experience in the insurance industry, I've witnessed its evolution, particularly the growing need for digital transformation in insurance underwriting. This transition is to deliver a more cost-effective and precise approach to assessing the appropriate coverage for individuals. Unisure is an ideal collaborator for the initial implementation of the BHA underwriting solution. We will launch the program involving a minimum of 5,000 participants, which will be crucial learnings in providing us with feedback and helping us shape the perfect product offering for the market. We value these participants immensely, as they represent a manageable segment for our solution's iterative development and refining.

“憑藉在保險行業二十多年的經驗,我親眼目睹了保險業的演變,尤其是保險承保領域對數字化轉型的需求不斷增長。這種過渡是爲了提供一種更具成本效益和更精確的方法來評估個人的適當承保範圍。Unisure是BHA承保解決方案初始實施的理想合作者。我們將啓動該計劃,至少有5,000名參與者,這將是向我們提供反饋和幫助我們爲市場塑造完美產品供應的關鍵知識。我們非常重視這些參與者,因爲他們代表了我們解決方案的迭代開發和完善的可管理部分。

AHI and SCOR, as partners, align perfectly with our philosophy and demonstrate a robust commitment to their clients. SCOR is a particularly suitable partner for AHI due to their client-centric approach. They customise their reinsurance solutions to meet their client's individual needs and risk profiles. SCOR's experienced underwriters and risk analysts work in close collaboration with clients to create comprehensive yet cost-effective risk strategies. This shared philosophy will be instrumental in our success as we move forward."

作爲合作伙伴,AHI和SCOR完全符合我們的理念,並表現出對客戶的堅定承諾。SCOR是AHI特別合適的合作伙伴,因爲他們以客戶爲中心。他們量身定製再保險解決方案,以滿足客戶的個人需求和風險狀況。SCOR經驗豐富的承銷商和風險分析師與客戶密切合作,制定全面且具有成本效益的風險策略。在我們向前邁進的過程中,這種共同的理念將對我們的成功起到重要作用。”

Vlado Bosanac, AHI Founder and Head of Strategy, said:

AHI創始人兼戰略主管弗拉多·博薩納克說:

"This Letter of Intent (LOI) brings a significant partnership to AHI with SCOR and Unisure Group. The collaboration signifies a major milestone in our journey to demonstrate to the insurance industry the powerful data AHI delivers to assist the industry in better understanding their policyholders, their health and the appropriate coverage they need. By leveraging AHI's innovative technology with the industry knowledge brought by SCOR and Unisure's expertise, we are poised to create a world-first on-device biometric digital underwriting solution. This partnership enhances our industry understanding of digital insurance tools and positions AHI at the forefront of the digital insurance revolution, unlocking cost-effective solutions for the unpenetrated middle market."

“這份意向書(LOI)爲AHI帶來了與SCOR和Unisure集團的重要合作伙伴關係。此次合作標誌着我們向保險業展示AHI提供的強大數據,以幫助該行業更好地了解保單持有人、他們的健康狀況和他們所需的適當保險,這是我們旅程中的一個重要里程碑。通過利用AHI的創新技術以及SCOR帶來的行業知識和Unisure的專業知識,我們有望創建世界上第一個設備上生物識別數字承保解決方案。這種合作關係增強了我們行業對數字保險工具的理解,使AHI處於數字保險革命的最前沿,爲尚未滲透的中間市場解鎖了具有成本效益的解決方案。”

AHI anticipates that revenue generation through this agreement will commence upon the initial deployment of the solution. The Company will continuously update our shareholders regarding the progress leading up to and including the commercial launch.

AHI預計,通過該協議創收將在該解決方案的初始部署時開始。公司將不斷向股東通報商業發佈之前和包括商業發佈在內的進展情況。

This announcement has been approved by the Chairman and CEO of Advanced Health Intelligence Ltd.

本公告已獲得高級健康情報有限公司董事長兼首席執行官的批准。

For more information, contact:

欲了解更多信息,請聯繫:

Dylan Garnett
Chief Innovation Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

迪倫·加內特
首席創新官
高級健康情報有限公司
E: admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

弗拉多·博薩納克
創始人/戰略主管
高級健康情報有限公司
E: admin@ahi.tech

About Unisure Group

關於 Unisure 集團

Unisure is an international health and life insurance solutions provider with offices on four continents. They provide SMEs with Group Life and Disability and Group Business Protection insurance solutions, as well as personalised solutions for employers who have employees that travel across borders. Unisure also provides individuals with a range of international life insurance solutions. They have their own medical clinics in Zambia and offer International Private Medical Insurance solutions globally. They distribute their solutions through intermediaries, insurance brokers and financial advisers.

Unisure是一家國際健康和人壽保險解決方案提供商,在四大洲設有辦事處。他們爲中小企業提供團體人壽和傷殘保險和團體商業保障保險解決方案,併爲有員工跨境旅行的僱主提供個性化解決方案。Unisure還爲個人提供一系列國際人壽保險解決方案。他們在贊比亞擁有自己的醫療診所,並在全球範圍內提供國際私人醫療保險解決方案。他們通過中介機構、保險經紀人和財務顧問分發解決方案。

Unisure's vision is to be a loved and trusted global insurance provider, protecting one million families every year through dynamic, equitable, and fully portable insurance solutions.

Unisure的願景是成爲備受喜愛和值得信賴的全球保險提供商,通過動態、公平和完全便攜的保險解決方案,每年爲100萬個家庭提供保護。

For more information, visit and .

欲了解更多信息,請訪問和。

About SCOR

關於 SCOR

SCOR, a leading global reinsurer, offers its clients a diversified and innovative range of reinsurance and insurance solutions and services to control and manage risk. Applying "The Art & Science of Risk", SCOR uses its industry-recognized expertise and cutting-edge financial solutions to serve its clients and contribute to the welfare and resilience of society. SCOR offers its clients a Tier 1 reinsurer rating from Standard & Poor's, AM Best, Moody's and Fitch. The Group generated premiums of EUR 19.7 billion in 2022 and serves clients in more than 160 countries from its 35 offices worldwide. For more information, visit: .

全球領先的再保險公司SCOR爲其客戶提供多樣化和創新的再保險和保險解決方案和服務,以控制和管理風險。SCOR運用 “風險的藝術與科學”,利用其行業公認的專業知識和尖端的金融解決方案爲客戶提供服務,併爲社會的福利和韌性做出貢獻。SCOR爲其客戶提供標準普爾、AM Best、穆迪和惠譽的一級再保險公司評級。集團在2022年創造了197億歐元的保費,並通過其全球35個辦事處爲160多個國家的客戶提供服務。欲了解更多信息,請訪問:。

About Advanced Health Intelligence Ltd

關於先進健康情報有限公司

Advanced Health Intelligence Ltd ('AHI') delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.

Advanced Health Intelligence Ltd(“AHI”)通過我們的專有技術和流程,爲全球醫療保健提供者、保險公司、僱主和政府機構提供可擴展的健康評估、風險分層和數字分診功能。

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:

自2014年以來,AHI一直通過智能手機提供健康技術創新,首先是世界上第一個設備端的身體體積測量功能。AHI開發了一項專利技術,通過一套組件化解決方案展示了醫療保健數字化的下一個前沿,最終實現了:

  • Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
  • Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
  • Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
  • On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
  • Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.
  • 身體尺寸和成分評估,以確定肥胖的合併症,例如糖尿病風險估計。
  • 血液生物標誌物預測,包括HbA1c、HDL、LDL和10年死亡風險。
  • 透皮光學成像可返回生命體徵和心血管疾病風險估計。
  • 在 133 個類別的 588 種皮膚狀況(包括黑色素瘤)中進行設備端皮膚病學皮膚識別;以及
  • 協助合作伙伴提供個性化的治療和非治療性健康指導,以改善日常習慣並培養健康素養。

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers.

我們由機器學習、人工智能、計算機視覺和受過醫學培訓的數據科學家組成的世界一流的主題專家團隊確保 AHI 的技術處於創新和消費者需求的最前沿。

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

AHI專注於大規模影響,很自豪能夠展示數字醫療轉型的這一里程碑,提供可通過智能手機訪問的生物識別衍生分診解決方案。藉助這些先進技術,AHI可以幫助其合作伙伴識別消費者的風險,並將其分類爲正確的護理途徑,以便在人羣規模上進行積極的健康管理。

For more information, please visit:

欲了解更多信息,請訪問:

Cautionary Note Regarding Forward-Looking Statements:

關於前瞻性陳述的警示說明:

This news release contains information or statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.

本新聞稿包含構成 “前瞻性陳述” 的信息或陳述。此類前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際業績、業績或成就或事態發展與此類前瞻性陳述所表達或暗示的預期結果、業績或成就存在重大差異。前瞻性陳述不是歷史事實,通常但並非總是用 “期望”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛力” 和類似表達方式等詞語來識別,或者事件或條件 “將”、“將”、“可能” 或 “應該” 發生。

Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of Advance Health Intelligence, and includes statements about, among other things, future developments and the future operations, strengths, and strategies of Advance Health Intelligence. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.

前瞻性信息可能包括但不限於有關Advance Health Intelligence的運營、業務、財務狀況、預期財務業績、業績、前景、機遇、優先事項、目標、目標、持續目標、里程碑、戰略和前景的陳述,還包括有關Advance Health Intelligence未來發展和未來運營、優勢和戰略的陳述。提供前瞻性信息的目的是提供有關管理層當前預期和未來計劃的信息,提醒讀者,此類陳述可能不適合其他目的。這些聲明不應被視爲未來業績或業績的保證。

The forward-looking statements made, or perceived to be made, in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analysis, and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavorable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Advanced Health Intelligence's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.

本新聞稿中作出或預計將發表的前瞻性陳述基於管理層的假設和分析以及管理層可能用來得出結論和進行預測或預測的其他因素,包括管理層的經驗以及對歷史趨勢、當前狀況和預期未來發展的評估。儘管管理層認爲,在本新聞稿中發表聲明時,這些假設、分析和評估是合理的,但實際結果可能與任何前瞻性陳述中的預測存在重大差異。可能導致實際業績與前瞻性陳述存在重大差異的風險和因素示例可能包括:監管行動的時機和不可預測性;與其運營或業務相關的監管、立法、法律或其他發展;營銷和銷售能力有限;行業和產品開發的早期階段;產品有限;對第三方的依賴;不利的宣傳或消費者看法;總體經濟狀況和金融市場;競爭加劇的影響;關鍵的損失管理人員;資本要求和流動性;獲得資本的機會;資本支出的時間和金額;COVID-19 的影響;對Advanced Health Intelligence產品的需求和市場規模的變化;專利法改革;專利訴訟和知識產權;利益衝突;以及總體市場和經濟狀況。

The forward-looking information contained in this news release represents the expectations of Advance Health Intelligence as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Advance Health Intelligence undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

本新聞稿中包含的前瞻性信息代表了Advance Health Intelligence截至本新聞稿發佈之日的預期,因此,該日期之後可能會發生變化。讀者不應過分重視前瞻性信息,也不應像其他任何日期一樣依賴這些信息。如果管理層的信念、估計或觀點或其他因素髮生變化,Advance Health Intelligence沒有義務更新這些前瞻性陳述。

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論